Here are six notes:
1. The shares have positive gains on 0.05 percent in the last four weeks.
2. The shares outperformed the S&P by 1.98 percent and the outperformance rose to 1.1 percent within the last four weeks.
3. The company has a recommended consensus of “Buy” this week.
4. The stock has dropped 8.72 percent during the last three month period.
5. The 52-week high of the share price is $38.94 and the 52-week low is $26.96.
6. The company has a market cap of $625 million.
More on devices:
Amedica signs additional OEM letter of intent supply agreement: 5 things to know
Stryker earnings skyrocket 206%: 10 key notes on 2Q
National neurosurgery registry wins CMS PQRS approval: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
